Sep 4, 2024 07:01AM
Sep 4, 2024 07:00AM
Aug 7, 2024 07:00AM
Jun 26, 2024 08:01AM
Jun 26, 2024 08:00AM
May 8, 2024 07:00AM
May 6, 2024 07:03AM EyePoint (EYPT) Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy Did Not Meet its Primary Endpoint
May 6, 2024 07:00AM
Apr 2, 2024 07:00AM
Mar 7, 2024 07:00AM
Mar 4, 2024 07:03AM
Mar 4, 2024 07:00AM
Feb 4, 2024 09:03AM
Feb 3, 2024 04:20PM EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular
Jan 10, 2024 07:00AM
Dec 4, 2023 07:01AM
Dec 4, 2023 07:00AM
Mar 27, 2023 07:00AM
Mar 20, 2023 07:00AM
Mar 2, 2023 07:00AM
Feb 27, 2023 07:00AM EyePoint Pharmaceuticals (EYPT) and Rallybio Enter Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 and EyePoint’s Proprietary Durasert Technology
Feb 27, 2023 07:00AM
Feb 27, 2023 07:00AM
Jan 23, 2023 07:10AM
Jan 23, 2023 07:00AM
Jan 5, 2023 07:00AM
Jan 4, 2023 07:00AM
Nov 2, 2022 07:00AM EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments
Sep 29, 2022 07:00AM
Aug 3, 2022 07:00AM
Aug 1, 2022 07:00AM
Jul 18, 2022 07:30AM
Jul 15, 2022 08:57AM
Jul 15, 2022 08:57AM
Jun 21, 2022 07:02AM EyePoint Pharmaceuticals (EYPT) and OcuMension Therapeutics Announce Approval of NDA by China’s NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment o
Jun 21, 2022 07:00AM
May 4, 2022 07:30AM
Mar 7, 2022 07:00AM
Mar 3, 2022 07:00AM
Feb 14, 2022 05:40AM
Feb 12, 2022 08:10AM
Nov 3, 2021 07:00AM EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
Nov 1, 2021 07:04AM
Nov 1, 2021 07:00AM
Oct 12, 2021 03:00PM
Oct 12, 2021 03:00PM
Sep 17, 2021 07:00AM
Aug 4, 2021 07:00AM
Aug 2, 2021 07:00AM EyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board
Jul 20, 2021 07:00AM

436,668 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All